Bioengineered veins could help patients needing bypass surgery, dialysis

June 2011
Edge (East Carolina University);Summer2011, p7
The article discusses the bioengineered veins developed by biotechnology company Humacyte and East Carolina University researchers in North Carolina. It says that the veins are tissue-engineered vascular grafts that can be immediately used during bypass surgery with minimal risk of infection or obstruction. It adds that the veins could also be used by patients on chronic hemodialysis and in other large- and small-diameter applications.


Related Articles

  • MorfoloÅ¡ke promene u aortokoronarnom venskom graftu -- analiza autopsijskog i biopsijskog materijala. Tatic, Vujadin; Kanjuh, Vladimir; Rafajlovski, Saso; Suscevie, Dusan; Ilie, Kadoje // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Sep/Oct2004, Vol. 61 Issue 5, p499 

    Background. Patients with implanted aortic coronary grafts have different survival time, which raises the question why the efficacy of graft implants is so poor. The aim of this study was to present the results of the analysis of morphological changes in the vein grafts taken after the death of...

  • Tibial Artery Revascularization Utilizing Microscopic Vascular Technique. Tomikawa, Masaki; Ueyama, Takeshi; Yokokawa, Masayasu; Hashimoto, Hideki; Yamamoto, Keiichi // Vascular Surgery;Sep1990, Vol. 24 Issue 7, p475 

    During the past six years and nine months, tibial artery revascularization was performed for 42 cases (47 limbs) utilizing the transmicroscopic vascular technique. The operations for limb salvage of the clinical stages III and IV accounted for 89.4% of all operations. Fifty-two operations were...

  • Lower extremity vein graft failure: a translational approach. Owens, Christopher D.; Ho, Karen J.; Conte, Michael S. // Vascular Medicine;2008, Vol. 13 Issue 1, p63 

    Patients with the most severe manifestations of lower extremity arterial occlusive disease often require peripheral bypass surgery for limb salvage and preservation of function. Although good quality saphenous vein offers the most durable conduit for reconstruction, 5-year failure rates are...

  • Hypothesis: A Potential Role for the Vasa Vasorum in the Maintenance of Vein Graft Patency. Dashwood, Michael R.; Anand, Radhi; Loesch, Andrzej; Souza, Domingos S. R. // Angiology;Jul/Aug2004, Vol. 55 Issue 4, p385 

    Autologous saphenous vein is the most commonly used conduit for coronary artery bypass surgery with more than 50% grafts occluding within 10 years. In conventional preparation the vein undergoes considerable surgical trauma with damage to the outer layers during harvesting. Within these regions...

  • Coronary Artery Bypass Grafting With Y-Saphenous Vein Grafts. Hulusi, Melih; Basaran, Murat; Ugurlucan, Murat; Kocailik, Ali; Basaran, Eylul Kafali // Angiology;Dec2009, Vol. 60 Issue 6, p668 

    Introduction: The saphenous vein is one of the indispensible grafts for coronary revascularization despite the advantages of arterial grafts over veins. It can be used in different configurations with different anastomosis (eg, sequential, composite, or Y-graft) techniques. Our aim was to...

  • Vein graft failure: current clinical practice and potential for gene therapeutics. Wan, S; George, S J; Berry, C; Baker, A H // Gene Therapy;Jun2012, Vol. 19 Issue 6, p630 

    Autologous saphenous vein is commonly used as a conduit to bypass atherosclerotic lesions in coronary and femoral arteries. Despite the wide use of arterial conduits, which are less susceptible to complications and failure, as alternative conduits, the saphenous vein will continue to be used in...

  • Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts. Ute Reisinger; Stefan Schwaiger; Iris Zeller; Barbara Messner; Robert Stigler; Dominik Wiedemann; Tobias Mayr; Christoph Seger; Thomas Schachner; Verena M. Dirsch; Angelika M. Vollmar; Johannes O. Bonatti; Hermann Stuppner; Günther Laufer; David Bernhard // Cardiovascular Research;Jun2009, Vol. 82 Issue 3, p542 

    : Aims Despite the lower patency of venous compared with arterial coronary artery bypass grafts, ∼50% of grafts used are saphenous vein conduits because of their easier accessibility. In a search for ways to increase venous graft patency, we applied the results of a previous pharmacological...

  • Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA. Meng, Q-H; Irvine, S; Tagalakis, A D; McAnulty, R J; McEwan, J R; Hart, S L // Gene Therapy;Oct2013, Vol. 20 Issue 10, p979 

    Vein graft failure caused by neointimal hyperplasia (IH) after coronary artery bypass grafting with saphenous veins is a major clinical problem. The lack of safe and efficient vectors for vascular gene transfer has significantly hindered progress in this field. We have developed a...

  • Off-pump coronary artery bypass grafting in patients on chronic hemodialysis. Olgun Kucuk, H.; Kucuk, U.; Cansiz, K. H.; Balta, S.; Arslan, Z. // European Review for Medical & Pharmacological Sciences;May2014, Vol. 18 Issue 9, p1434 

    A letter to the editor is presented in response to an article about coronary artery bypass graft (CABG) surgery in hemodialysis patients in a 2013 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics